Recombinant Human Amyloid beta A4 Protein

Catalog #: DRA20 Derived From: Human Cells

Description:

Recombinant Human Amyloid β A4 Protein/APP is produced by our Mammalian expression system and the target gene encoding Leu18-Leu305 is expressed with a 6His tag at the C-terminus.

Accession: P05067-2

Names(Known as):Amyloid Beta A4 Protein; ABPP; APPI; APP; Alzheimer Disease Amyloid Protein; CerebralVascularAmyloid Peptide; CVAP; PreA4; Protease Nexin-II; PN-II; APP

Quality Control:

Mol Mass: 33.6kDa AP Mol Mass: 50kDa, reducing conditions

Purity: Greater than 95% as determined by reducing SDS-PAGE.

Formulation:

Supplied as a 0.2 μm filtered solution of 20mM PB,150mM NaCl,pH7.4.

Shipping:

The product is shipped on dry ice pack.

Upon receipt, store it immediately at the temperature listed below.

Storage:

Reconstituted protein solution should be stored at ≤ -20°C.

Purification: 
Affinity purification chromatography.

Immunoreactivity: 
N.A.

Application:
Immunogen, calibrator or standard.

Background:

Amyloid β A4 Protein (APP) is an integral membrane protein that belongs to the APP family. APP contains one BPTI/Kunitz inhibitor domain. APP is expressed in all fetal tissues, with the highest expression levels observed in the brain, kidney, heart, and spleen. APP is a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion, and axonogenesis. APP plays a role in cell mobility and transcription regulation through protein-protein interactions. APP also promotes transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Mutations in APP are associated with Alzheimer's disease.

FOR RESEARCH OR FURTHER MANUFACTURING USE ONLY